Umeå University's logo

umu.sePublications
Planned maintenance
A system upgrade is planned for 10/12-2024, at 12:00-13:00. During this time DiVA will be unavailable.
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression
Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria.
Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria; Department of Pathology, Medical University of Vienna, Vienna, Austria; Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria; Department of Pathology, Medical University of Vienna, Vienna, Austria; Biochemical Institute, University of Kiel, Kiel, Germany.
Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria; Department of Cell Biology, Charles University, Prague, Czech Republic and Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University (BIOCEV), Vestec u Prahy, Czech Republic.
Show others and affiliations
2024 (English)In: Molecular Cancer, E-ISSN 1476-4598, Vol. 23, no 1, article id 114Article in journal (Refereed) Published
Abstract [en]

Background: Prostate cancer develops through malignant transformation of the prostate epithelium in a stepwise, mutation-driven process. Although activator protein-1 transcription factors such as JUN have been implicated as potential oncogenic drivers, the molecular programs contributing to prostate cancer progression are not fully understood.

Methods: We analyzed JUN expression in clinical prostate cancer samples across different stages and investigated its functional role in a Pten-deficient mouse model. We performed histopathological examinations, transcriptomic analyses and explored the senescence-associated secretory phenotype in the tumor microenvironment.

Results: Elevated JUN levels characterized early-stage prostate cancer and predicted improved survival in human and murine samples. Immune-phenotyping of Pten-deficient prostates revealed high accumulation of tumor-infiltrating leukocytes, particularly innate immune cells, neutrophils and macrophages as well as high levels of STAT3 activation and IL-1β production. Jun depletion in a Pten-deficient background prevented immune cell attraction which was accompanied by significant reduction of active STAT3 and IL-1β and accelerated prostate tumor growth. Comparative transcriptome profiling of prostate epithelial cells revealed a senescence-associated gene signature, upregulation of pro-inflammatory processes involved in immune cell attraction and of chemokines such as IL-1β, TNF-α, CCL3 and CCL8 in Pten-deficient prostates. Strikingly, JUN depletion reversed both the senescence-associated secretory phenotype and senescence-associated immune cell infiltration but had no impact on cell cycle arrest. As a result, JUN depletion in Pten-deficient prostates interfered with the senescence-associated immune clearance and accelerated tumor growth.

Conclusions: Our results suggest that JUN acts as tumor-suppressor and decelerates the progression of prostate cancer by transcriptional regulation of senescence- and inflammation-associated genes. This study opens avenues for novel treatment strategies that could impede disease progression and improve patient outcomes. Graphical Abstract: (Figure presented.).

Place, publisher, year, edition, pages
BioMed Central (BMC), 2024. Vol. 23, no 1, article id 114
Keywords [en]
AP-1 transcription factors, Immune infiltration, JUN, Prostate cancer, SASP, Senescence
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:umu:diva-225946DOI: 10.1186/s12943-024-02022-xISI: 001234826100001PubMedID: 38811984Scopus ID: 2-s2.0-85194834139OAI: oai:DiVA.org:umu-225946DiVA, id: diva2:1868919
Funder
EU, Horizon 2020, 675712Available from: 2024-06-12 Created: 2024-06-12 Last updated: 2024-10-21Bibliographically approved

Open Access in DiVA

fulltext(4335 kB)39 downloads
File information
File name FULLTEXT01.pdfFile size 4335 kBChecksum SHA-512
5c8ea818e2014852af4099ddea116f417efae2b78f3d60f3b68dbdeaee235050779918a4de4d0652af0a3ed056ee2bab778e44b5ca4ddb43ab0a11c7d295d63d
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Persson, Jenny L.Kenner, Lukas

Search in DiVA

By author/editor
Persson, Jenny L.Kenner, Lukas
By organisation
Department of Molecular Biology (Faculty of Medicine)
In the same journal
Molecular Cancer
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 39 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 208 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf